Uma Borate, MD
Hematology · Columbus, OHNPI 1619182946
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $264,656 of the $322,505 with a category attached, or 82.1%. It is spread thinly across 27 manufacturers, the largest accounting for just 23.0%. Among hematology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 311 payments — averaging $1036.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$74K
- Novartis$49K
- Daiichi Sankyo Inc.$32K
- Incyte Corporation$26K
- E.r. Squibb & Sons, L.L.C.$25K
- Astellas Pharma Global Development$20K
- plus $97K from 21 others
Across 754 payments — averaging $31,124 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$15.1M
- AbbVie$2.1M
- Pfizer$1.6M
- Incyte Corporation$1.2M
- Jazz Pharmaceuticals Inc.$1.1M
- Astellas Pharma Global Development$654K
- plus $1.8M from 14 others
What the payments were for
- Consulting fees$264,65682%
- Speaking & faculty fees$6,6072%
- Grants$1,8751%
- Travel & lodging$41,94513%
- Food & beverage$7,2102%
- Education$2120%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 65 | $74,041 |
| Novartis | 25 | $48,528 |
| Daiichi Sankyo Inc. | 42 | $32,060 |
| Incyte Corporation | 33 | $26,235 |
| E.r. Squibb & Sons, L.L.C. | 22 | $24,556 |
| Astellas Pharma Global Development | 3 | $19,995 |
| Bristol Myers Squibb | 33 | $16,908 |
| Genentech USA, Inc. | 13 | $11,943 |
| Astellas Pharma US Inc | 13 | $10,914 |
| Servier Pharmaceuticals LLC | 9 | $9,310 |
| Syndax Pharmaceuticals, Inc. | 11 | $8,748 |
| Jazz Pharmaceuticals Inc. | 5 | $6,896 |
| Agios Pharmaceuticals, Inc. | 2 | $6,006 |
| Geron Corporation | 6 | $5,798 |
| Sumitomo Pharma America, Inc. | 2 | $3,508 |
| Immunogen, Inc. | 5 | $3,429 |
| Janssen Scientific Affairs, LLC | 4 | $2,806 |
| Blueprint Medicines Corporation | 1 | $2,340 |
| Genentech, Inc. | 3 | $2,339 |
| Gilead | 3 | $1,760 |
| F. Hoffmann-la Roche AG | 3 | $1,670 |
| Hexal AG | 1 | $1,350 |
| Genmab U.S., Inc. | 1 | $785 |
| AstraZeneca | 1 | $160 |
| Janssen Research & Development, LLC | 1 | $146 |
| Stemline Therapeutics Inc. | 2 | $139 |
| Rigel Pharmaceuticals, Inc. | 2 | $133 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$322,505 in reported general payments places this provider in the 95th percentile of 84 hematology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 32 | $609,837 |
| SprycelDasatinib | 29 | $370,108 |
| OnuregAzacitidine | 14 | $362,065 |
| OjjaaraMomelotinib Dihydrochloride | 13 | $331,244 |
| ScemblixAsciminib Hydrochloride | 12 | $257,940 |
| RevlimidLenalidomide | 11 | $257,632 |
| IclusigPonatinib Hcl | 11 | $215,531 |
| VenclextaVenetoclax | 72 | $96,083 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| E.r. Squibb & Sons, L.L.C.Sprycel, Onureg | $24,556 | $732,17343 claims |
| Incyte CorporationJakafi | $26,235 | $609,83732 claims |
| NovartisScemblix | $48,528 | $257,94012 claims |
| Bristol Myers SquibbRevlimid | $16,908 | $257,63211 claims |
| AbbVieVenclexta | $74,041 | $96,08372 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 84 hematology providers in Ohio.
Other hematology in Columbus
- Sam PenzaColumbus$256K
- Spero CatalandColumbus$245K
- Kami MaddocksColumbus$236K
- Narendranath EpperlaColumbus$199K
- Yvonne EfeberaColumbus$169K
- Naresh BummaColumbus$109K
- Kerry RogersColumbus$100K
- Jennifer WoyachColumbus$73K
- Hannah ChoeColumbus$72K
- Alice MimsColumbus$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.